Table 2.

Univariable and Multivariable Logistic Regression Analyses of Clinicopathologic Features to Overall Survival in Rectal Cancer Patients Receiving Neoadjuvant Therapy (N=2260)

Variables		Univariate 95% CI	Multivariablea 95% CI	P-value
Lymph node yield
	<12	Ref	Ref
	≥12	1.20(0.99–1.46)	1.33(1.06–1.66)	0.0124
Gender
	Male	0.86(0.69–1.06)	0.79(0.63–1.01)	0.0548
	Female	Ref.	Ref.
Age groups
	≤ 65	Ref.	Ref.
	>65	0.64(0.53–0.78)	0.61(0.49–0.76)	<0.0001
Grade
	Well/Moderately	Ref.	Ref.
	Poorly/ Undifferentiated	0.27(0.20–0.38)	0.40(0.27–0.58)	<0.0001
Pathologic T stage
	ypT0	Ref.	Ref.
	ypT1	0.95(0.38–1.84)	0.90(0.41–1.94)	0.7777
	ypT2	0.60(0.31–1.17)	0.59(0.36–0.97)	0.0373
	ypT3	0.25(0.13–0.47)	0.28(0.18–0.45)	<0.0001
	ypT4	0.11(0.05–0.23)	0.17(0.09–0.31)	<0.0001
Pathologic N stage
	ypN0	Ref.	Ref.
	ypN1	0.51(0.40–0.64)	0.63(0.49–0.81)	0.0004
	ypN2	0.23(0.18–0.31)	0.32(0.23–0.45)	<0.0001
Charlson comorbidity
	0–1	Ref.	Ref.
	2–3	0.70(0.51–0.97)	0.65(0.46–0.93)	0.0195
	≧4	0.64(0.35–1.17)	0.49(0.25–0.98)	0.0421
Margin
	Positive	0.26(0.17–0.41)	0.36(0.22–0.60)	<0.0001
	Negative	Ref.	Ref.
Adjuvant chemotherapy	No	0.85(0.69–1.05)	0.68(0.54–0.87)	0.0020
	Yes	Ref.	Ref.
Surgery type
	APR	0.61(0.48–0.77)	0.79(0.60–1.04)	0.096
	LAR	Ref.	Ref.
	Protectomy	0.78(0.25–2.46)	0.76(0.21–2.74)	0.6757
	Unknown	0.93(0.70–1.24)	1.02(0.75–1.41)	0.8857

Note: ^aAdjusted for all the variables in the univariate list and diagnosed year of cancer.